Aurobindo Pharma's biologics arm CuraTeQ Biologics is preparing to commercialise its bevacizumab biosimilar Bevqolva in Canada after receiving a Notice of Compliance from Health Canada, marking a significant expansion of the Indian pharmaceutical group's oncology footprint in a major Western market. The approval, announced Monday, positions Bevqolva as a lower-cost alternative to Roche's Avastin, one of the world's best-selling cancer therapies, used widely in colorectal, lung, cervical, and ovarian cancers.

Industry analysts tracking Canada's oncology biosimilar segment said the timing of the approval is significant, coinciding with growing pressure from provincial health ministries to accelerate substitution policies for high-cost biologics. Ontario and British Columbia, which together account for more than half of Canada's cancer drug spending, are expected to review Bevqolva's inclusion on their respective formularies in coming weeks, potentially unlocking substantial volume for CuraTeQ.

Bevacizumab biosimilars have already captured meaningful market share in the United States and Europe following approvals for competing products from Pfizer, Amgen, and Samsung Bioepis. Canada has lagged peer nations in biosimilar uptake, but a 2024 federal policy directive encouraging provincial substitution has steadily shifted purchasing patterns. CuraTeQ's entry adds another approved option and is expected to intensify price competition among existing biosimilar suppliers already present in the Canadian market.

Aurobindo Pharma, headquartered in Hyderabad, has been systematically building its biologics portfolio through CuraTeQ as part of a broader strategy to diversify beyond small-molecule generics. The Canadian approval follows earlier regulatory successes for the unit in other markets and comes alongside parent company Zydus Lifesciences' separate acquisition moves in Europe, reflecting a wider wave of Indian pharma expansion into high-value therapeutic categories.

CuraTeQ has not yet publicly disclosed Canadian pricing or distribution partnerships, but analysts expect the company to target a discount of 25 to 35 percent below Avastin's current list price, consistent with bevacizumab biosimilar pricing dynamics observed elsewhere. Canadian oncologists and hospital pharmacists are expected to begin reviewing Bevqolva clinical data and supply terms in preparation for potential procurement decisions later in the second quarter of 2026.